Linda Peckel

All articles by Linda Peckel

Vector-Borne Illnesses

A tetravalent dengue vaccine candidate (TDV) was found to be safe and immunogenic in an ongoing phase 2 trial. A second TDV dose induced enhanced immunogenicity against DENV-3 and DENV-4 in children who were seronegative before vaccination, supporting the initiation of phase 3 trial to evaluate the efficacy and safety of TDV given in a 2-dose schedule 3 months apart.